A study comparing treatment outcomes according to different procedural approaches in the treatment of atrial fibrillation

The Effect of Right Atrial Ablation Added to Pulmonary Vein Isolation in Atrial Fibrillation Catheter Ablation: A Prospective Randomized Clinical Trial (EARPOD Trial)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011581

Enrollment

444

Registered

2026-02-05

Start date

2024-02-14

Completion date

Unknown

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : The right atrial SVC–septal line is a linear ablation extending from the highest septal site where the catheter electrode is positioned toward the septal aspect of the superior ven

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 20 to 80 years with paroxysmal atrial fibrillation (sustained for < 7 days) who are candidates for catheter ablation. 2. Patients with atrial fibrillation and a left atrial size < 50 mm. 3. Patients with paroxysmal atrial fibrillation who have experienced recurrence despite anti-arrhythmic drug therapy, or for whom anti-arrhythmic drug therapy is contraindicated or not tolerated. 4. Patients who are eligible for anticoagulation therapy (antithrombotic treatment for the prevention of ischemic stroke).

Exclusion criteria

Exclusion criteria: 1. Patients with atrial fibrillation and a left atrial anteroposterior diameter = 50 mm 2. Atrial fibrillation associated with severe congenital heart disease or structural heart disease with significant hemodynamic impact 3. Patients with severe renal dysfunction or those unable to undergo contrast-enhanced CT imaging 4. Patients with active internal bleeding 5. Contraindications to anticoagulation therapy (for stroke prevention) or anti-arrhythmic drug therapy 6. Valvular atrial fibrillation (mitral stenosis > grade 2, mechanical heart valve, or prior mitral valve repair) 7. Patients with clinically significant severe comorbid conditions 8. Patients with an expected life expectancy of less than 1 year 9. Patients with drug or alcohol abuse 10. Patients unable to read the informed consent form (e.g., illiteracy, foreign nationals unable to understand the language) 11. Any other condition that, in the investigator’s judgment, makes the patient unsuitable for participation in the clinical trial

Design outcomes

Primary

Measure	Time frame
Atrial fibrillation recurrence during the follow-up period after ablation	—

Secondary

Measure	Time frame
Procedure time;Occurrence of additional atrial arrhythmias;Radiofrequency ablation time	—

Countries

Korea, Republic of

Contacts

Public ContactHui-nam Park

Yonsei University Health System, Severance Hospital

hnpak@yuhs.ac+82-2-2228-8459

Outcome results